Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
Onconetix (NASDAQ:ONCO) and Ocuvex Therapeutics have mutually agreed to terminate their merger agreement originally announced on July 16, 2025. The decision comes after both companies determined that pursuing independent paths would better serve their respective stakeholders.
Despite the merger termination, Ocuvex announced positive developments, including obtaining its New Jersey state pharmaceutical license and the upcoming commercial launch of Omlonti in the coming weeks. Both companies' leadership expressed confidence in their independent growth trajectories and maintained a collaborative spirit throughout the process.
Onconetix (NASDAQ:ONCO) e Ocuvex Therapeutics hanno concordato reciprocamente di terminare il loro accordo di fusione annunciato originariamente il 16 luglio 2025. La decisione è arrivata dopo che entrambe le aziende hanno ritenuto che seguire percorsi indipendenti servirebbe meglio i rispettivi stakeholder.
Nonostante la terminazione della fusione, Ocuvex ha annunciato sviluppi positivi, tra cui l’ottenimento della licenza farmaceutica statale del New Jersey e il prossimo lancio commerciale di Omlonti nelle prossime settimane. Le leadership di entrambe le aziende hanno espresso fiducia nelle loro traiettorie di crescita indipendenti e hanno mantenuto uno spirito di collaborazione durante tutto il processo.
Onconetix (NASDAQ:ONCO) y han acordado mutuamente terminar su acuerdo de fusión anunciado originalmente el 16 de julio de 2025. La decisión surge tras determinar que seguir rutas independientes serviría mejor a sus respectivas partes interesadas.
A pesar de la terminación de la fusión, Ocuvex anunció desarrollos positivos, incluida la obtención de su licencia farmacéutica estatal de Nueva Jersey y el próximo lanzamiento comercial de Omlonti en las próximas semanas. Los líderes de ambas compañías expresaron confianza en sus trayectorias de crecimiento independientes y mantuvieron un espíritu de colaboración a lo largo del proceso.
Onconetix (NASDAQ:ONCO)와 Ocuvex Therapeutics는 2025년 7월 16일에 처음 발표된 합병 계약을 상호 합의로 해지하기로 했다. 이 결정은 두 회사 모두 독립적인 경로를 추구하는 것이 각 이해관계자들에게 더 나은 가치를 제공할 것이라고 판단한 데 따른 것이다.
합병 종료에도 불구하고 Ocuvex는 긍정적 발전을 발표했다. 뉴저지 주 제약 면허 취득 및 조만간 예정된 Omlonti의 상용 출시가 그 예이다. 양사 리더십은 독립적인 성장 궤도에 자신감을 표명했고, 전 과정에 걸쳐 협력적 분위기를 유지했다.
Onconetix (NASDAQ : ONCO) et Ocuvex Therapeutics ont convenu d’un commun accord de mettre fin à leur accord de fusion annoncé initialement le 16 juillet 2025. Cette décision résulte du fait que les deux entreprises estiment que suivre des chemins indépendants serait mieux pour leurs parties prenantes respectives.
Malgré la fin de la fusion, Ocuvex a annoncé des développements positifs, notamment l’obtention de sa licence pharmaceutique d’État du New Jersey et le prochain lancement commercial de Omlonti dans les prochaines semaines. La direction des deux sociétés a exprimé sa confiance dans leurs trajectoires de croissance indépendantes et a maintenu un esprit de collaboration tout au long du processus.
Onconetix (NASDAQ:ONCO) und Ocuvex Therapeutics haben einvernehmlich beschlossen, ihre ursprünglich am 16. Juli 2025 bekannt gegebene Fusionsvereinbarung zu beenden. Die Entscheidung ergibt sich daraus, dass beide Unternehmen erkannt haben, unabhängige Wege würden ihren jeweiligen Stakeholdern besser dienen.
Trotz der Beendigung der Fusion gab Ocuvex positive Entwicklungen bekannt, darunter der Erwerb seiner staatlichen Arzneimittel-Lizenz aus New Jersey und der kommende kommerzielle Start von Omlonti in den nächsten Wochen. Die Führung beider Unternehmen zeigte Zuversicht in ihren unabhängigen Wachstumsbahnen und bewahrte während des gesamten Prozesses einen kooperativen Geist.
اتفقت Onconetix (ناسداك:ONCO) و Ocuvex Therapeutics بشكل متبادل على إنهاء اتفاق الاندماج الذي أعلن عنه في الأصل في 16 يوليو 2025. يأتي القرار بعد أن قررت كلتا الشركتين أن متابعة مسارات مستقلة ستخدم أصحاب المصلحة لديهم بشكل أفضل.
وعلى الرغم من إنهاء الاندماج، أعلنت Ocuvex عن تطورات إيجابية، بما في ذلك حصولها على رخصة الأدوية الحكومية لولاية نيوجيرسي واستعدادها لإطلاق تجاري لـ Omlonti خلال الأسابيع المقبلة. عبرتقيادات الشركتين عن ثقتها في مسارات النمو المستقلة وظلتا روح التعاون طوال العملية.
Onconetix（纳斯达克股票代码：ONCO）与 Ocuvex Therapeutics 已就其于 2025 年 7 月 16 日最初宣布的合并协议相互同意终止。此决定源于两家公司均认为追求独立路径将更有利于各自的利益相关者。
尽管合并终止，Ocuvex 宣布了积极进展，包括获得新泽西州药品许可，以及未来几周内将正式上市的 Omlonti。两家公司的领导层对各自独立的增长轨迹表示信心，并在整个过程中保持了合作精神。
- Ocuvex secured New Jersey state pharmaceutical license
- Ocuvex's Omlonti product launch proceeding as planned
- Both companies maintain strong independent growth prospects
- Loss of potential synergies from the planned merger
- Strategic expansion plans through merger discontinued
- Potential market opportunities from combined operations foregone
CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a leader in ophthalmic innovation, today announced the mutual termination of their previously announced definitive merger agreement, dated July 16, 2025.
After careful consideration and constructive dialogue, both companies have jointly determined that pursuing independent paths is in the best interests of their respective stakeholders. This decision reflects the strong commitment of both Onconetix and Ocuvex to advancing their respective missions and delivering value to patients, partners, and investors.
Anthony Amato, CEO of Ocuvex, commented: "The decision to mutually terminate the merger agreement does not impact Ocuvex’s momentum or our commitment to patients. We are excited to announce that Ocuvex has received its New Jersey state pharmaceutical license, and the commercial launch of Omlonti will commence in the coming weeks. Our pipeline continues to advance, and we remain focused on delivering innovative ophthalmic solutions to the market."
Andrew Oakley, Chairman of the Board of Onconetix, added: "Ocuvex is an innovative company with a strong commitment to advancing eye health. Despite our decision to part ways, we are confident that Omlonti will deliver value for patients and the ophthalmic community upon launch and future growth."
Both organizations express appreciation for the collaborative spirit and professionalism shown throughout the merger discussions.
About Onconetix, Inc.
Onconetix (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology. Through its acquisition of Proteomedix, Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union (“EU”) under the IVDR. For more information, visit www.onconetix.com.
About Ocuvex Therapeutics, Inc.
Ocuvex is dedicated to advancing ophthalmic science and improving patient outcomes through innovative research and product development. For more information, visit www.ocuvextherapeutics.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to various risks and uncertainties. Please refer to each company’s filings with the Securities and Exchange Commission for more information.
Contact Information:
Onconetix, Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, OH 45202
Phone: (513) 620-4101
Investor Relations: investors@onconetix.com
Ocuvex Therapeutics, Inc.
1 Bridge Plaza, 2nd Floor
Fort Lee, NJ 07024
Phone: 551-258-2635
Investor Relations: info@ocuvextherapeutics.com
FAQ
Why did Onconetix (NASDAQ:ONCO) and Ocuvex terminate their merger agreement?
When was the original merger agreement between Onconetix and Ocuvex announced?
What are Ocuvex's plans following the terminated merger with Onconetix?
How will the merger termination affect Onconetix's (NASDAQ:ONCO) business operations?
What is the current status of Ocuvex's product pipeline after the terminated merger?
